Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly

Herlev Hospital22 enrolled

Overview

To test the hypothesis that both lack and excess of growth hormone (GH) is associated with cardiac abnormalities. Cardiac function and morphology will be evaluated by MRI before and after treatment.

It is an open prospective noninterventional clinical study. Treatment and follow-up will be according to usual guidelines, and will be unaffected by inclusion in the study. GHD patients will be treated with daily subcutaneous GH injections. Patients with acromegaly will be treated with either transsphenoidal surgery or by medical treatment with long acting somatostatin analogues, dopamine agonist, GH antagonist or combinations of these treatment modalities. Patients will be examined by Cardiac MRI before treatment and after one year of treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Growth Hormone Deficiency Cardiac Function

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Peak GH below 6.0 ng/mL during Pyridostigmine-GHRH test. * Nadir GH above 0.4 ng/mL and elevated levels of IGF-I during oral glucose tolerance test Exclusion Criteria: * Contraindications for magnetic resonance scan

Outcomes

Primary Outcomes

Changes in cardiac function i relation to changes in the activity of the GH-axis

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.